<DOC>
	<DOCNO>NCT03017378</DOCNO>
	<brief_summary>The study single centre , phase I , open , randomize , intranasal sublingual application trial explore safety immunogenicity 2 dos ( Day 1 Day 21 ) TB/FLU-01L tuberculosis vaccine BCG-vaccinated healthy adult subject age 18-50 year .</brief_summary>
	<brief_title>Reactogenicity , Safety Immunogenicity TB/FLU-01L Tuberculosis Vaccine</brief_title>
	<detailed_description />
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy BCGvaccinated male female adult 18 50 year age enrollment visit . Literate willing provide write informed consent . A sign informed consent . Capable willing complete diary card willing return followup visit . For female , willing take reliable birth control measure throughout entire period participation study Clinical , radiological ( chest Xray ) laboratory evidence active past TB disease . Current past administration antiTB therapy . History contact TB patient . Positive QuantiFERONTB Gold test . BCG vaccination le 6 month prior study . Practice nasal irrigation regular basis within past six month engage nasal irrigation within two week prior enrollment . Recent history frequent nose bleeds ( &gt; 5 within past year ) . Clinically relevant abnormal paranasal anatomy . Recent history ( within past month ) rhino sinus surgery , surgery traumatic injury nose . Current recent ( within two week enrollment ) acute respiratory illness without fever . Hypersensitivity previous administration vaccine . History chronic alcohol abuse and/or illegal drug use . Any clinically significant abnormal laboratory finding . A positive pregnancy test woman childbearing potential . Administration immunosuppressive drug immune modify drug within 4 week prior study enrollment . Acute chronic clinically significant pulmonary disease , cardiovascular disease , gastrointestinal disease , liver disease , neurological illness , liver disease , blood disease , skin disorder , endocrine disorder , neurological illness psychiatric disorder determine medical history , physical examination clinical laboratory screening test , opinion investigator , might interfere study objective . History leukemia blood solid organ cancer . Seropositive HIV , hepatitis B surface antigen and/or hepatitis C antibody . Receipt antiviral , antibiotic , immunoglobulin blood product within 4 week prior study enrollment plan receipt product period subject participation study . Participation another clinical trial within previous three month plan enrollment trial period study . Subjects , opinion investigator , significantly increase risk noncooperation requirement study protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>influenza vector</keyword>
	<keyword>tuberculosis</keyword>
	<keyword>vaccine</keyword>
</DOC>